{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014768","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.588306+00:00","generated_at":"2026-05-30T03:42:54.483730+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aprea Therapeutics Reports Q3 2024 Financial Results; Cash $26.2M, Net Loss $3.8M","bullets":["Cash and cash equivalents of $26.2 million as of Sept 30, 2024, providing at least twelve months of runway.","Operating loss of $4.1 million for Q3 2024 versus $3.5 million in Q3 2023; net loss of $3.8 million ($0.64 per share).","Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 shows well-tolerated profile with no unexpected toxicities at subtherapeutic doses.","Phase 1/2a ABOYA-119 trial of ATR inhibitor ATRN-119 enrolling at dose level 6 (800 mg QD); twice-daily dosing added to protocol.","Engaged Philippe Pultar, MD as senior medical advisor in October 2024 to support APR-1051 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014768","json":"https://secwatch.observer/filing/0001558370-24-014768.json","markdown":"https://secwatch.observer/filing/0001558370-24-014768.md","text":"https://secwatch.observer/filing/0001558370-24-014768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024014768/0001558370-24-014768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024014768/apre-20241107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:42:54.483730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}